Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle

This article was originally published in PharmAsia News

Executive Summary

MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck

You may also be interested in...



Indo Nippon: A New Sun Rises To Link Indian And Japanese Drug Firms

In search of business opportunities, several Indian and Japanese drug makers have come under one roof to identify joint projects. The architect of the new initiative is Satish Khanna, an industry veteran who has seen successes with similar ventures in the past.

Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved

A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.

Headway Seen In EU-India FTA Talks, Commerce Ministry Joint Secretary Says

Disputes over EU blockades of Indian drug shipments are still on the negotiation table, says Commerce Ministry. India hopes to initiate talks with China as well.

Related Content

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel